Home › Research › Prevention and risk
Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis
Martina Mancini, Mitra Afshari, Quincy J. Almeida, Sommer L. Amundsen Huffmaster, Katherine Balfany, Richard M. Camicioli, Cory L. Christiansen, Marian L. Dale et al.. npj Parkinson s Disease, 2025-03-21
Topic: Brain proteins, microglia and lab models
Plain-language summary
This narrative review examines the utility of gait digital biomarkers in Parkinson's disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. The review of the literature to date suggests that upper body characteristics of gait (e.g., arm swing, trunk motion) may indicate susceptibility/risk of PD, while pace aspects (e.g., gait speed, stride length) are informative for tracking disease progression, exercise response, and fall likelihood. Dynamic stability aspects (e.g., trunk regularity, double-support time) worsen with disease progression but can improve with exercise. Gait variability emerges as a sensitive biomarker across all 4 contexts but with low specificity. The lack of standardized gait testing protocols and the lack of a minimum set of quantified digital gait biomarkers limit data harmonization across studies. Future studies, using a commonly agreed upon protocol, could be used to demonstrate the utility of specific gait biomarkers for clinical practice.
What this study adds
Evidence grade: Low
This is a narrative review. This review is about digital gait biomarkers in Parkinson's disease for tracking risk, progression, exercise response, and falls. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mancini, M., Afshari, M., Almeida, Q. J., Huffmaster, S. L. A., Balfany, K., Camicioli, R. M., et al. (2025). Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis. npj Parkinson s Disease. https://doi.org/10.1038/s41531-025-00897-1
Vancouver
Mancini M, Afshari M, Almeida QJ, Huffmaster SLA, Balfany K, Camicioli RM, et al. Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis. npj Parkinson s Disease. 2025. doi:10.1038/s41531-025-00897-1. PMID: 40118834.
BibTeX
@article{mancini2025-40118834,
author = {Mancini, Martina and Afshari, Mitra and Almeida, Quincy J. and Huffmaster, Sommer L. Amundsen and Balfany, Katherine and Camicioli, Richard M. and Christiansen, Cory L. and Dale, Marian L. and others},
title = {{Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis}},
journal = {npj Parkinson s Disease},
year = {2025},
doi = {10.1038/s41531-025-00897-1},
pmid = {40118834},
url = {https://doi.org/10.1038/s41531-025-00897-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The review of the literature to date suggests that upper body characteristics of gait (e.g., arm swing, trunk motion) may indicate susceptibility/risk of PD, while pace aspects (e.g., gait speed, stride length) are informative for tracking disease progression, exercise response, and fall likelihood.
Why it matters
This review is about digital gait biomarkers in Parkinson's disease for tracking risk, progression, exercise response, and falls. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designnarrative review
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (npj Parkinson s Disease) |
| Journal's citation record | 1 / 4 | Npj Parkinson s Disease: journal h-index 87 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 49 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 6 / 6 | Cited 107.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 49 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Daniel M. Corcos: h-index 69 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40118834) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41531-025-00897-1
- PubMed: 40118834
- Original source →
- Free full text: npj Parkinson s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Prevention and risk from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.